Last updated October 21, 2026. Approval line checked October 21, 2026. No compounding source date is assigned.
FDA status
Not approved
Not approved. This record is not an FDA-approved drug product. Approval, where it exists, is specific to a drug product, indication, and route.
FDA: Unapproved drugsBy signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Evidence tier
Human Observational. The tier is the highest indexed study type. It is not a safety rating and it is not an FDA approval. Confidence score 3/5. 915 PubMed citations indexed.
Ginsenoside Rg3 is a steroidal saponin triterpenoid from Panax ginseng with peptide-adjacent pharmacology that modulates multiple signaling pathways including NF-κB suppression, Nrf2 activation for an
What the literature studies
Immune Research
Evidence tier
Human Observational
Compounding record
Status not verified
Status not verified. No product-specific FDA primary source is recorded for this entry. FDA approval and compounding eligibility are not verified. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route.
Regulatory source not verified; no checked date is assigned.
RG3 is a non-peptide triterpenoid saponin categorized as 'peptide-adjacent'; its extremely poor oral bioavailability (<5%) means most supplemental forms provide minimal systemic ex
By signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Educational only. Not medical advice. This page does not give doses or sourcing. See the medical and editorial disclaimer.